BIOBIJOU Co., Ltd. Logo

BIOBIJOU Co., Ltd.

Develops and manufactures injectable aesthetic solutions like HA fillers for global markets.

489460 | KO

Overview

Corporate Details

ISIN(s):
KR7489460006
LEI:
Country:
South Korea
Address:
경기도 하남시 하남대로 947 에이동 1516호, 하남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BIOBIJOU Co., Ltd. is a global medical aesthetics company established in 2018. It specializes in the research, development, manufacturing, and sale of injectable products such as skin boosters, hyaluronic acid (HA) fillers, and fat-dissolving solutions, alongside other cosmetic items. The company manages an integrated value chain, from R&D and product design to production in its own GMP-certified facilities and global distribution. BIOBIJOU has established a robust sales network, exporting to over ten countries with a strong presence in the Chinese market. Through strategic R&D alliances and investment in high-level manufacturing, the company aims to deliver high-quality, competitively priced aesthetic solutions to the global market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 89.4 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.8 KB
2025-05-20 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.9 KB
2025-05-13 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 211.9 KB
2025-05-02 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 495.1 KB
2025-05-02 00:00
Prospectus
[기재정정]투자설명서
Korean 3.6 MB
2025-04-29 00:00
Prospectus
투자설명서
Korean 3.1 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.1 MB
2025-04-07 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.0 MB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]감사보고서 (2024.12)
Korean 493.5 KB
2025-03-24 00:00
Annual / Quarterly Financial Statement
[기재정정]연결감사보고서 (2024.12)
Korean 504.6 KB
2025-03-24 00:00
Registration Form
증권신고서(지분증권)
Korean 3.0 MB
2025-03-18 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 488.6 KB
2025-03-18 00:00
Audit Report / Information
연결감사보고서 (2024.12)
Korean 499.7 KB

Automate Your Workflow. Get a real-time feed of all BIOBIJOU Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOBIJOU Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOBIJOU Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.